SCHEMBL11599337

SCHEMBL11599337

CC(C)(C)OC(=O)N[C@H](CCC(=O)OCc1ccccc1)C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.53
KLK7 P49862 1/20 0.51
KLK5 Q9Y337 1/20 0.51
CTSS P25774 4/20 0.50
PPARG P37231 2/20 0.50
SYK P43405 1/20 0.50
CTSK P43235 4/20 0.49
ACE P12821 1/20 0.49
REN P00797 2/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
CTSL P07711 2/20 0.48
CTSB P07858 1/20 0.48
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 1/20 0.47
TLR2 O60603 1/20 0.46
TLR1 Q15399 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997847 1.00 PPARA (0.53) PPARAKLK7KLK5CTSSPPARG
SCHEMBL10887447 1.00 PPARA (0.53) PPARAKLK7KLK5CTSSPPARG
Hydrochloric Acid SCHEMBL11597785 0.99 PPARA (0.52) PPARAKLK7KLK5CTSSPPARG
SCHEMBL11599295 0.93 CTSL (0.60) CTSSCTSKACERENCTSL
SCHEMBL11598828 0.93 REN (0.53) PPARAKLK7KLK5CTSSCTSK
SCHEMBL11597960 0.92 REN (0.50) PPARAKLK7KLK5CTSSPPARG
SCHEMBL8984141 0.92 PPARA (0.54) PPARAKLK7KLK5CTSSPPARG
SCHEMBL25384406 0.92 REN (0.49) PPARAKLK7KLK5CTSSSYK
SCHEMBL21778857 0.92 REN (0.49) PPARAKLK7KLK5CTSSSYK
SCHEMBL11647966 0.92 REN (0.49) PPARAKLK7KLK5CTSSSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170237-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF UNIVERSITEIT GENT (BE) 2025-05-29 US disclosed
EP-4482849-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2025-01-01 EP disclosed
US-12134664-B2 Muramyl peptide derivatives BHARAT BIOTECH INTERNATIONAL LTD. (IN) 2024-11-05 US disclosed
WO-2023161962-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-08-31 WO disclosed
EP-3389643-B1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INT LTD (IN) 2023-05-03 EP disclosed
EP-3389643-B1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INT LTD (IN) 2023-05-03 EP disclosed
CN-108884132-B Muramyl peptide derivatives a compound their synthesis and their use 巴拉特生物技术国际有限公司 2022-10-04 CN disclosed
EP-3387005-B1 NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF BHARAT BIOTECH INT LTD (IN) 2022-08-24 EP disclosed
US-9085605-B2 Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2015-07-21 US disclosed
US-20130143826-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2013-06-06 US disclosed
US-20130143826-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2013-06-06 US disclosed
US-4082736-A NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF SYNTEX (U.S.A.) INC. (US) 1978-04-04 US disclosed
US-4082735-A NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF SYNTEX (U.S.A.) INC. (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12134664-B2 Muramyl peptide derivatives NOD2, NGLY1, LNPEP PPARA 1402/4885KLK7 2576/4885KLK5 3233/4885
US-20250170237-A1 MURAMYL DIPEPTIDES AND PROCESS FOR PREPARATION THEREOF NOD2, NOD1, TLR9 PPARA 1827/4885KLK7 3524/4885KLK5 3787/4885
US-20130143826-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE PTMS, DNPEP, PAICS PPARA 1204/4885KLK7 2545/4885KLK5 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.